J. Goldman & Co’s Pacira BioSciences PCRX Stock Holding History

J. Goldman & Co’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$560K	Sell	22,078 -75,694	-77%	-$1.79M	0.01%	540
2026 Q1	$2.21M	Sell	97,772 -339,481	-78%	-$7.54M	0.06%	307
2025 Q4	$11.3M	Sell	437,253 -231,887	-35%	-$5.51M	0.3%	97
2025 Q3	$17.2M	Buy	669,140 +12,576	+2%	+$309K	0.43%	68
2025 Q2	$15.7M	Sell	656,564 -202,567	-24%	-$5.11M	0.38%	87
2025 Q1	$21.3M	Buy	859,131 +731,988	+576%	+$17.5M	0.53%	48
2024 Q4	$2.4M	Buy	+127,143	New	+$2.23M	0.06%	265
2023 Q3	–	Sell	-51,931	Closed	-$2.08M	–	456
2023 Q2	$2.08M	Buy	+51,931	New	+$2.15M	0.08%	206
2020 Q1	–	Sell	-40,325	Closed	-$1.83M	–	319
2019 Q4	$1.83M	Buy	+40,325	New	+$1.71M	0.13%	148
2019 Q3	–	Sell	-90,418	Closed	-$3.61M	–	339
2019 Q2	$3.93M	Buy	+90,418	New	+$3.84M	0.27%	113
2018 Q3	–	Sell	-35,895	Closed	-$1.15M	–	362
2018 Q2	$1.15M	Buy	+35,895	New	+$1.24M	0.06%	248
2017 Q4	–	Sell	-203,400	Closed	-$7.64M	–	412
2017 Q3	$7.64M	Buy	+203,400	New	+$8.18M	0.39%	78

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

J. Goldman & Co's PCRX Position: Q2 2026 in Review

J. Goldman & Co reduced its Pacira BioSciences (PCRX) stake by 77% in Q2 2026, selling an estimated $1.79M and leaving 22,078 shares worth $560K. The position accounts for 0.01% of the portfolio, ranked #540.

J. Goldman & Co first reported a position in PCRX in Q3 2017 and has held it in 12 quarters since. The position peaked at $21.3M in Q1 2025. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

J. Goldman & Co held 22,078 shares of Pacira BioSciences worth $560K as of Q2 2026.
J. Goldman & Co sold 75,694 Pacira BioSciences shares in Q2 2026, an estimated $1.79M.
Pacira BioSciences made up 0.01% of J. Goldman & Co's portfolio in Q2 2026, its #540 holding.
J. Goldman & Co first reported a position in Pacira BioSciences in Q3 2017 and has held it in 12 quarters since.
J. Goldman & Co's Pacira BioSciences position peaked at $21.3M in Q1 2025.
253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.